Atrium Therapeutics, Inc. Common Stock

Day range

$8.02 – $8.23

Open

$8.20

Prev close

$8.20

Volume

108.75K

Market cap

$140.27M

Shares out

17.11M

• Underwriting agreementOct 8, 2026

  Leerink Partners LLC acted as lead placement agent in the Offering. Cantor Fitzgerald & Co., Barclays Capital Inc. and Wells Fargo Securities, LLC acted as placement agents in the Offering.

• Regulatory decisionJul 14, 2026

  the U.S. Food and Drug Administration has cleared its Investigational New Drug ("IND") application allowing the Company to move forward with its CorventisTM Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 ("PRKAG2") syndrome.

• Control acquisitionFeb 27, 2026

  As a result of the consummation of the Merger, there was a change in control of the Company, and the Company became a wholly owned subsidiary of Parent.

• Merger agreementFeb 26, 2026

  The Agreement and Plan of Merger, dated as of October 25, 2025, among Novartis AG, Ajax Acquisition Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent, and the Company, was approved by stockholders at the Special Meeting.

• Executive compensation changeDec 18, 2025

  The Board approved the acceleration into December 2025 of the vesting and payments of certain equity awards and annual cash bonuses, respectively, that otherwise would have been payable to Ms. Boyce, Dr. Flanagan, Ms. McCarthy and Mr. Moriarty and certain other Company executives...These actions are intended to benefit the Company by preserving potential compensation-related corporate income tax deductions for the Company that otherwise might be disallowed through the operation of Section 280G.

Days to cover

8.3

Short interest

3.4M

Avg volume

410.85K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Halper Sadeh LLC Encourages TWO, RNA, CVBF, TBN Shareholders to Contact the Firm to Discuss Their Rights
  negativeGlobeNewswire Inc.· Jan 31, 2026
• $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBHC, RNA, NEW, and TWO
  negativeBenzinga· Jan 30, 2026
• Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights
  neutralGlobeNewswire Inc.· Nov 22, 2025
• Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
  positiveBenzinga· Nov 20, 2025
• Novartis Maintains Outlook Even As Generics Bite Into Profits
  neutralBenzinga· Oct 28, 2025